NEW YORK, Aug. 31, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel‘s foremost medical research center, announced today that its CEO, Mr. Ophir Shahaf, will present at the Rodman & Renshaw Annual Global Investment Conference in New York City on Tuesday, September 13, 2011 at 12:05 p.m. ET. The conference will be held at the Waldorf Astoria Hotel.
Investors attending the conference who wish to meet with Mr. Shahaf for a one-on-one meeting should contact their Rodman & Renshaw representative directly.
About Hadasit Bio-Holdings:
Hadasit Bio-Holdings Ltd., established in 2006, is the publicly traded subsidiary of Hadasit Ltd. - the technology transfer company of the Hadassah University Hospital, Israel‘s foremost medical research center. The Company was established for the purpose of promoting and commercializing the intellectual property and R&D capabilities generated by Hadassah.
HADSY is the domestically traded ADR of Hadasit Bio-Holdings, a public investment vehicle representing a portfolio of biotech companies, all based on inventions developed at Hadassah.
Hadasit Bio-Holdings focuses on advancing companies that are past successful preclinical trials and close to completion of Phase I/II clinical trials. The portfolio companies develop drugs with blockbuster potential (markets that are worth over a billion dollars) and operate in the fields of cancer, inflammatory diseases and tissue regeneration using stem cells - areas in which the Hadassah Hospital has extensive knowledge and recognition as a global leader.
For more information please visit: www.hbl.co.il.
Investor Contact
KCSA Strategic Communications
Jeff Corbin / Rob Fink
rfink@kcsa.com
(212) 896-1206
SOURCE Hadasit Bio-Holdings, Ltd.
